Baird lowered the firm’s price target on Neurogene (NGNE) to $46 from $72 and keeps an Outperform rating on the shares. The firm updated its model for 3Q24 earnings and to further take into consideration the update of a trial participant in critical condition after receiving the high dose of NGN-401. The lower price target reflects lowering its projected share of the Rett syndrome gene therapy market that goes to NGN-401 to 50%.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene selloff on safety event an overreaction, says H.C. Wainwright
- Closing Bell Movers: Super Micro up 28% on compliance update
- Neurogene reports Q3 EPS ($1.19), consensus ($1.22)
- Neurogene Adjusts NGN-401 Trial After Adverse Event
- Neurogene provides update on NGN-401 clinical trial for Rett syndrome